Interpretation of European clinical practice guidelines for oligometastatic esophagogastric cancer
- VernacularTitle:《欧洲寡转移食管胃癌临床实践指南》解读
- Author:
Xiaofeng DUAN
1
;
Shangren WANG
1
;
Jie YUE
1
;
Hongjing JIANG
1
Author Information
1. Department of Minimally Invasive Surgery, National Clinical Research Center for Cancer, Tianjin's Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, P. R. China
- Publication Type:Journal Article
- Keywords:
Esophagogastric cancer;
oligometastasis;
guideline interpretation
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2025;32(04):463-468
- CountryChina
- Language:Chinese
-
Abstract:
In recent years, with the clinical application of minimally invasive surgical techniques and comprehensive preoperative treatment, the survival rate of locally advanced esophageal cancer has significantly improved. However, the treatment of metastatic esophagogastric cancer still relies mainly on systemic therapy, and immunotherapy combined with chemotherapy has become a first-line treatment option, prolonging the survival of patients with metastatic esophageal cancer. Oligometastatic esophageal cancer is expected to bring survival benefits through systemic therapy combined with local treatment. The 2024 European clinical practice guidelines for oligometastatic esophagogastric cancer have been officially released, which standardize the definition, diagnosis, and treatment of oligometastatic esophageal cancer for further prospective studies. The authors interpret this guideline, especially by reviewing the clinical evidence of oligometastatic esophageal squamous cell carcinoma, to provide reference for the diagnosis and treatment of oligometastatic esophageal cancer in China.
